HS0004

Evaluate the efficacy of bimekizumab in study participants with moderate to severe HS

A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Bimekizumab in Study Participants with Moderate to Severe Hidradenitis Suppurativa

Key Eligibility Criteria

Study participants must have a diagnosis of HS for at least 6 months prior to the Baseline visit

Therapeutic Area

Hidradenitis Supperativa

Type of Study

Clinical trial

Study Status

Closed

Sponsor

UCB Biopharma SRL

Principal Investigator

Professor Brian Kirby

Contact

Binita.maharjan@ucd.ie